4D Molecular Therapeutics reported a wider adjusted loss of $1.08 per share for Q3 2026, missing analyst expectations. However, the company's revenue reached $4.15 million, surpassing both estimates and last year's figures, continuing a trend of strong revenue growth. Despite the loss, the company has beaten revenue estimates in three of the past four quarters, indicating potential for future improvement. Investors should watch upcoming quarters for signs of profitability progress.
4D Molecular Therapeutics Q3 2026 results provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 08:21 WIB: out of 150 priced US health-sector stocks, 28 rose and 120 fell. Notable movers include SANA at USD 2.03 with a 1-day change of -11.35%, CTXR at USD 0.53 with +11.19%, and NVAX at USD 8.88 with -11.02%. Typical hold times range from 19 to 60 days, with varying buy/sell order activity.
Atlas Energy Corp. completed its first royalty acquisition for $15 million on producing oil and gas assets in Southwest Alberta, funded by cash. The company began generating royalty revenue immediately, earning $141,000 in just seven days post-acquis...
AELO Swiss Academy has transformed into an international airline pilot training organization with bases in Locarno, Lugano, and Cuneo, reflecting over 40 years of aviation heritage. The academy reported a 186% increase in operations in September 2026...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Upbit has suspended deposits and withdrawals of Osmosis (OSMO) tokens due to the Osmosis Chain network ceasing block production. This suspension means customers cannot move OSMO tokens onto or off the Upbit platform via the Osmosis Chain. However, tr...
